Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
US Army
Express Scripts
Chubb
Federal Trade Commission
Medtronic
Deloitte
QuintilesIMS
Dow

Generated: May 21, 2018

DrugPatentWatch Database Preview

Javelin Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for JAVELIN PHARMS INC, and what generic alternatives to JAVELIN PHARMS INC drugs are available?

JAVELIN PHARMS INC has one approved drug.

There are two US patents protecting JAVELIN PHARMS INC drugs.

There are twenty-four patent family members on JAVELIN PHARMS INC drugs in eleven countries.

Summary for Javelin Pharms Inc
International Patents:24
US Patents:2
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Javelin Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Javelin Pharms Inc DYLOJECT diclofenac sodium SOLUTION;INTRAVENOUS 022396-001 Dec 23, 2014 RX Yes Yes 8,946,292 ➤ Try a Free Trial ➤ Try a Free Trial
Javelin Pharms Inc DYLOJECT diclofenac sodium SOLUTION;INTRAVENOUS 022396-001 Dec 23, 2014 RX Yes Yes 6,407,079 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for JAVELIN PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 37.5 mg/mL, 1 mL single-dose vials ➤ Subscribe 2015-12-15

Non-Orange Book US Patents for Javelin Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,580,954 Formulations of low dose diclofenac and beta-cyclodextrin ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Queensland Health
Teva
Dow
Citi
Medtronic
Colorcon
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.